Vanda Pharmaceuticals, ‘Hetlioz’, drug to to treat non-24-hour sleep-wake disorder receives FDA’s nod
On January 31, 2013, The U.S Drug and Food Administration (FDA) approved Hetlioz (tasimelteon) to treat non-24-hour sleep-wake disorder in totally blind individuals. Hetlioz works as a melatonin receptor agonist More...